Cold forming partnership leads to development of drug delivery system
Dawson Shanahan and Zogenix work together on Sumavel DosePro
Dawson Shanahan partnered Zogenix on development of the Sumavel DosePro (sumatriptan injection) system, a drug-device combination that enables needle-free delivery of subcutaneous sumatriptan for the acute treatment of migraines and cluster headaches.
‘Our client had heard of the benefits of cold forming in terms of both quality and manufacturing cost savings and approached us to produce one component of the DosePro device by cold forming,’ said Mark Jennings at Dawson Shanahan. ‘They were so impressed with our innovative solution that they then asked us to make a second component, again to demanding tolerances.’
Dawson Shanahan began to work closely with Zogenix to enhance the design of the DosePro system and manufactured a number of integral elements of the system in-house. With assistance from Simon West at E-Tech, the company created the bespoke machining and tooling needed to manufacture one of the components and together they developed and tested the parts until an optimum solution was found.
Dawson Shanahan engineered an aluminium chamber and steel ram to administer the drug without requiring a needle. The company says the success of the design is partly due to the high quality finish and intricate production of the cold-formed parts, which make it possible for the administration mechanism to work.
‘Throughout the manufacture process, Dawson Shanahan has been extremely collaborative, throwing the necessary resources at challenges to help us find the best solutions,’ said Bill Feinstein, director of operations planning and procurement at Zogenix.
Established in 1945, Dawson Shanahan employs 55 people in its 2,800m² purpose-built factory. The company is a precision manufacturer of components using cold forming, precision CNC machining and assembly. It specialises in the cold forming and finish machining of pure copper (OFHC), aluminium and ferrous components.
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more. -
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Drug Delivery
embecta completes £100m acquisition of UK-based Owen Mumford to bolster drug delivery portfolio
US diabetes care company embecta has finalised its acquisition of Owen Mumford, gaining access to the Aidaptus next-generation auto-injector platform as it accelerates its transition into a broad-based medical supplies company
Pharmaceutical
MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients
The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Drug Delivery
Wearable pumps and subcutaneous delivery: a new frontier in heart failure management
Two recent developments are reshaping how drug delivery technology can move treatment out of the clinic and into patients’ everyday lives — with implications for both formulation science and device manufacturing
Manufacturing
Lonza expands AAV offering with Xcite AAV stable Producer Cell Line platform to idustrialise Viral Vector Manufacturing
New technology demonstrates superior performance versus transient transfection in clinically relevant customer gene of interest and engineered capsid, enabling scalable and cost-effective AAV manufacturing. Launch reflects Lonza’s deep expertise in cell line development, viral vector manufacturing, and platform industrialisation built over decades of supporting complex biologics